Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.
Department of Epidemiology, Johns Hopkins University, Baltimore, MD, USA.
Curr Allergy Asthma Rep. 2023 Sep;23(9):481-496. doi: 10.1007/s11882-023-01102-0. Epub 2023 Jul 4.
In this review, we provide a comprehensive update on current scientific advances and emerging therapeutic approaches in the field of multiple sclerosis.
Multiple sclerosis (MS) is a common disorder characterized by inflammation and degeneration within the central nervous system (CNS). MS is the leading cause of non-traumatic disability in the young adult population. Through ongoing research, an improved understanding of the disease underlying mechanisms and contributing factors has been achieved. As a result, therapeutic advancements and interventions have been developed specifically targeting the inflammatory components that influence disease outcome. Recently, a new type of immunomodulatory treatment, known as Bruton tyrosine kinase (BTK) inhibitors, has surfaced as a promising tool to combat disease outcomes. Additionally, there is a renewed interested in Epstein-Barr virus (EBV) as a major potentiator of MS. Current research efforts are focused on addressing the gaps in our understanding of the pathogenesis of MS, particularly with respect to non-inflammatory drivers. Significant and compelling evidence suggests that the pathogenesis of MS is complex and requires a comprehensive, multilevel intervention strategy. This review aims to provide an overview of MS pathophysiology and highlights the most recent advances in disease-modifying therapies and other therapeutic interventions.
在这篇综述中，我们提供了多发性硬化症领域当前科学进展和新兴治疗方法的全面更新。
多发性硬化症（MS）是一种常见疾病，其特征是中枢神经系统（CNS）内的炎症和退化。MS 是年轻成年人群体中非创伤性残疾的主要原因。通过持续的研究，我们对疾病的潜在机制和促成因素有了更好的理解。因此，专门针对影响疾病结果的炎症成分，已经开发出治疗进展和干预措施。最近，一种新型免疫调节治疗方法，称为布鲁顿酪氨酸激酶（BTK）抑制剂，已成为对抗疾病结果的有前途的工具。此外，人们对 Epstein-Barr 病毒（EBV）作为 MS 的主要增强剂重新产生了兴趣。目前的研究工作集中在解决我们对 MS 发病机制理解中的差距上，特别是在非炎症驱动因素方面。有大量令人信服的证据表明，MS 的发病机制很复杂，需要一个全面的、多层次的干预策略。本综述旨在概述 MS 的病理生理学，并重点介绍疾病修饰治疗和其他治疗干预的最新进展。
